Disease progression velocity as predictor of severity in Guillain-Barre syndrome

Objective: To identify the velocity of disease progression as a predictor of severity in patients with Guillain-Barre syndrome (GBS). Materials and methods: Prospective observational study of patients with confirmed diagnosis of GBS between May and August 2019 in four hospitals in Peru. The disease...

Full description

Bibliographic Details
Main Authors: Raúl Montalvo, Alex Castañeda, Jorge A. López, Cecilia Mathey
Format: Article
Language:Spanish
Published: Instituto Nacional de Salud 2021-03-01
Series:Revista Peruana de Medicina Experimental y Salud Pública
Subjects:
Online Access:https://rpmesp.ins.gob.pe/index.php/rpmesp/article/view/5106
Description
Summary:Objective: To identify the velocity of disease progression as a predictor of severity in patients with Guillain-Barre syndrome (GBS). Materials and methods: Prospective observational study of patients with confirmed diagnosis of GBS between May and August 2019 in four hospitals in Peru. The disease progression velocity (DPV) was defined as the time since the onset of neurological symptoms and the maximum peak of neurological severity. Results: Of 94 cases with GBS, the average age was 42 years; 73 (77.8%) patients presented severe GBS, the average hospital stay was 19 days; 45 (47.8%) patients had diarrheal symptoms previously, in 63 (67.1%) patients the onset of motor weakness was located in the upper limbs and in 31 (32.9%) it was located in the lower limbs, 9 (10.0%) patients presented some type of dysautonomy; admission to mechanical ventilation was needed in 8 (8.5%) patients, and the deceased were 2 (2.0%). The DPV≤ 1 day has a 79% probability of developing severe disease, the two and three day DPV have the probability of 61% and 38% respectively of progressing to severe forms. Conclusion: DPV is a predictor of poor prognosis when it is less than 2 days and with a possible requirement for mechanical ventilation. The speed of progression of neurological disease is a practical and accessible clinical evaluation method that should be evaluated in patients with GBS.
ISSN:1726-4634
1726-4642